Ovarian cancer: Interplay of vitamin D signaling and miRNA action

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 8, 2014, Pages 3359-3362

  Attar, Rukset ^a   Gasparri, Maria Luisa ^b   Di Donato, Violante ^c   Yaylim, Ilhan ^d   Halim, Talha Abdul ^e   Zaman, Farrukh ^e   Farooqi, Ammad Ahmad ^f  

^a YEDITEPE UNIVERSITY   (Turkey)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d ISTANBUL UNIVERSITY   (Turkey)

^e Department of Obstetrics and Gynecology ^*  (Pakistan)

^f INSTITUTE OF BIOMEDICAL AND GENETIC ENGINEERING IBGE   (Pakistan)

Author keywords

Apoptosis; miRNA; Ovarian cancer; Signaling; VDR; Vitamin D

Indexed keywords

CALCITRIOL RECEPTOR; MICRORNA; VDR PROTEIN, HUMAN; VITAMIN D;

APOPTOSIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; SIGNAL TRANSDUCTION;

APOPTOSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; VITAMIN D;

EID: 84901989624     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.8.3359     Document Type: Article

References (30)

1. Alvarez-Diaz S, Valle N, Ferrer-Mayorga G, et al (2012) MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum Mol Genet,21, 2157-65.
2. Brard L, Lange TS, Robison K, et al (2011). Evaluation of the first ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines. Gynecol Oncol,123, 370-8.
3. Cai J, Yang C, Yang Q, (2013). Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis,7, 2-75.
4. Giangreco AA, Vaishnav A, Wagner D, et al (2013) Tumor suppressor microRNAs, miR-100 and-125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue. Cancer Prev Res,6, 483-94.
5. Gocek E, Wang X, Liu X, Liu CG, Studzinski GP (2011). MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to bim targeting and inhibition of AraC-induced apoptosis. Cancer Res,71, 6230-9.
6. Guan H, Liu C, Chen Z, et al (2013). 1,25-Dihydroxyvitamin D3 up-regulates expression of hsa-let-7a-2 through the interaction of VDR/VDRE in human lung cancer A549 cells. Gene,522, 142-6.
7. Guo Y, Tian P, Yang C, et al (2013). Silencing the double-stranded RNA binding protein DGCR8 inhibits ovarian cancer cell proliferation, migration, and invasion. Pharm Res, Oct 12, [Epub ahead of print].
8. Hossein G, Keshavarz M, Ahmadi S, Naderi N (2013). Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev,14, 7561-8.
9. House CD, Hernandez L, Annunziata CM (2014). Recent technological advances in using mouse models to study ovarian cancer. Front Oncol,13, 4-26.
10. Huang JW, Wang Y, Dhillon KK, et al (2013). Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res,11, 1564-73.
11. Ji T, Zheng ZG, Wang FM, et al (2014). Differential microRNA expression by solexa sequencing in the sera of ovarian cancer patients. Asian Pac J Cancer Prev,15, 1739-43.
12. Kasiappan R, Shen Z, Tse AK, et al (2012). 1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498. J Biol Chem,287, 41297-309.
13. Kawar N, Maclaughlan S, Horan TC, et al (2013). PT19c, another nonhypercalcemic vitamin D2 derivative, demonstrates antitumor efficacy in epithelial ovarian and endometrial cancer models. Genes Cancer,4, 524-34.
14. Kuang Y, Cai J, Li D, (2013). Repression of dicer is associated with invasive phenotype and chemoresistance in ovarian cancer. Oncol Lett,5, 1149-54.
15. Li D, Wang X, Wu JL, et al (2013). Tumor-produced versican V1 enhances hCAP18/LL-37 expression in macrophages through activation of TLR2 and vitamin D3 signaling to promote ovarian cancer progression in vitro. PLoS One, 8, 56616.
16. Li H, Cai Q, Godwin AK, Zhang R (2010). Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res,8, 1610-8.
17. Min D, Lv XB, Wang X, et al (2013). Downregulation of miR-302c and miR-520c by 1,25(OH)2D3 treatment enhances the susceptibility of tumour cells to natural killer cell-mediated cytotoxicity. Br J Cancer,109, 723-30.
18. Moore RG, Lange TS, Robinson K, et al (2012). Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model. PLoS One, 7, e34443.
19. Padi SK, Zhang Q, Rustum YM, Morrison C, Guo B (2013). MicroRNA-627 mediates the epigenetic mechanisms of vitamin D to suppress proliferation of human colorectal cancer cells and growth of xenograft tumors in mice. Gastroenterology,145, 437-46.
20. Patel JB, Patel KD, Patel SR, et al (2012). Recent candidate molecular markers: vitamin D signaling and apoptosis specific regulator of p53 (ASPP) in breast cancer. Asian Pac J Cancer Prev,13, 1727-35.
21. Qin X, Lu Y, Qin A, et al (2013). Vitamin D receptor BsmI polymorphism and ovarian cancer risk: a meta-analysis. Int J Gynecol Cancer,23, 1178-83.
22. Shen Z, Zhang X, Tang J, et al (2011). The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells. Mol Cell Endocrinol,338, 58-67.
23. Sun C, Li N, Zhou B, et al (2013). miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1. Oncol Lett,6, 507-512.
24. Walentowicz-Sadłecka M, Sadłecki P, Walentowicz P, Grabiec M (2013). The role of vitamin D in the carcinogenesis of breast and ovarian cancer. Ginekol Pol,84, 305-8.
25. Wan HF, Yu LH, Wu JL, et al (2013). Effect of diallyl trisulfide on human ovarian cancer SKOV-3/DDP cell apoptosis. Asian Pac J Cancer Prev,14, 7197-201.
26. Wang Z, Ting Z, Li Y, et al (2013). microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin. Oncol Lett,6, 789-794.
27. Wu Y, Zhang X, Lin L, et al (2014). Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer. Asian Pac J Cancer Prev,15, 1171-6.
28. Xu Y, He B, Pan Y, et al (2014). Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Tumour Biol, 35, 4153-69
29. Yin L, Grandi N, Raum E, (2011). Meta-analysis: circulating vitamin D and ovarian cancer risk. Gynecol Oncol,121, 69-75.
30. Zhang Y, Tong SC, Guan LH, (2013). Meta-analysis of the relation between vitamin D receptor gene BsmI polymorphism and susceptibility to ovarian cancer. Tumour Biol,34, 3317-21.